Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

SMALL-CAP WINNERS: Mears rises as annual profit set to beat forecasts

8th Dec 2025 10:59

(Alliance News) - The following stocks are the leading risers among London Main Market small-caps on Monday.

----------

SMALL-CAP - WINNERS

----------

Saga PLC, up 8.1% at 316.75 pence, 12-month range 111.6p-316.75p. The cruise operator's shares have continued to rise since Thursday, when UK hedge fund Kernow said its shares could increase by more than 400%.

----------

Mears Group PLC, up 4.7% at 371.75p, 12-month range 311.5p-417.5p. The provider of housing services to the UK public and regulated sectors says it has traded strongly in the second half to date. It expects adjusted pretax profit for 2025 to be at the top end of its market guidance issued in August, when it reiterated that the figure would be "modestly ahead of market expectations". Back in June, it set a minimum target of GBP54 million, higher than the company-cited consensus of GBP50.9 million.

----------

PureTech Health PLC, up 3.1% at 125.8p, 12-month range 103p-170p. Completes its end-of-phase 2 meeting with the US Food & Drug Administration to develop deupirfenidone for the treatment of idiopathic pulmonary fibrosis. Says the meeting was supported by results from the phase 2b ELEVATE IPF trial, in which participants treated with deupirfenidone experienced a slower rate of lung function decline versus those who were treated with pirfenidone or placebo. Its founded entity Celea Therapeutics expects to finalise financing in early 2026, to support the initiation of the phase 3 SURPASS-IPF trial in the first half of the year. The phase 3 study will compare deupirfenidone to pirfenidone in adults with idiopathic pulmonary fibrosis who are not on background therapy. PureTech adds that based on FDA feedback, it believes that successful results from the phase 3 trial could complete the data package required to support potential registration of deupirfenidone through a streamlined regulatory pathway.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to [email protected]

Copyright 2025 Alliance News Ltd. All Rights Reserved.


Related Shares:

SagaMearsPureTech
FTSE 100 Latest
Value9,641.67
Change-25.34